- 1 Title: Using Trends and Outliers in Managing Delayed Transfusions
- 2
- 3 Authors: Burak Bahar^{1,2 Δ}, Eric A. Gehrie^{3 Δ}, Yunchuan D. Mo^{1,2}, Cyril Jacquot^{1,2} and Meghan
- 4 Delaney^{1,2}
- 5 (1) Children's National Hospital, Washington, DC, USA
- 6 (2) George Washington University, School of Medicine and Health Sciences, Washington, DC,
- 7 USA
- 8 (3) American Red Cross, Washington, DC, USA
- 9 $^{\Delta}$ Co-first authors
- 10 Corresponding author:
- 11 Burak Bahar, MD
- 12 Children's National Hospital
- 13 111 Michigan Ave NW
- 14 Department of Laboratory Medicine
- 15 Washington, DC, USA
- 16 202-476-5858
- 17 <u>bbahar@childrensnational.org</u>
- 18
- 19
- 20
- 21
- 22
- 23

24 Abstract

25	Delayed transfusions may result in patient morbidity and mortality, but no standards for
26	timely transfusion have been developed. Information technology tools could be implemented to
27	identify gaps in provision of blood and to recognize areas of improvement. Herein, we propose
28	that the time to initiate a blood transfusion after an informative laboratory test could feasibly be
29	used by the transfusion medicine service as a metric to monitor for transfusion delays. Trends
30	and outlier events could be further investigated and used to make decisions and implement
31	protocols to improve patient care.
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

47 Introduction

48 An emerging area of focus within transfusion medicine is the possibility that efforts to 49 curtail unnecessary blood transfusions could unintentionally deprive patients of needed blood 50 transfusions (1). However, the ability to measure or detect transfusions that should have occurred 51 - but did not - is frustrated by the fact that transfusion medicine services generally begin their 52 review at the time of order receipt. In addition, blood shortages could deprive a patient of a 53 needed transfusion even if the clinical indication is recognized by the clinical service (1). The 54 Serious Hazard of Transfusion (SHOT) program defines delayed transfusion as "where a 55 transfusion of a blood component was clinically indicated but was not undertaken or non-56 availability of blood components led to a significant delay (e.g., that caused patient harm, 57 resulted in admission to ward or return on another occasion for transfusion)" and accepts reports 58 of such events (2). Since 2011, there has been is an increasing trend in the number of annual 59 delayed transfusion reports (3). Per the SHOT 2021 Annual Report, there were 179 delayed 60 transfusion reports and nine deaths in the UK in 2021 (3). SHOT recommended actions to 61 prevent transfusion delays include reviewing, updating and implementing policies, implementing 62 training programs and processes to audit and investigate all transfusion delays, and using appropriate investigation tools (4). We propose that the average (or median) time to initiate a 63 64 blood transfusion after an informative laboratory test (e.g., haemoglobin concentration or platelet 65 count below local threshold) could be used by the transfusion medicine service as an 66 investigation tool to assess transfusion delays. This metric could also be used to evaluate trends 67 and identify outlier events. This knowledge could help to implement approaches to improve 68 stewardship of the blood supply and minimize the impact of blood shortages.

69

3

70 Methods

71 From January 1st, 2020, to September 1st, 2022, all patients' complete blood cell (CBC) 72 result and red blood cell (RBC) and platelet transfusion data were extracted, transformed, and 73 loaded into previously described laboratory science platform our data 74 (https://github.com/bbahar/umay) (5) with additional custom R and SOL scripts 75 (https://github.com/bbahar/delayed-transfusions). The number of RBC and platelet transfusions 76 per week were calculated. Time from the release of laboratory results to the initiation of 77 transfusions were calculated and weekly medians were used for trend analyses. Variables of 78 interest for RBC transfusions were haemoglobin level (<7g/dL and $\geq 7g/dL$), RBC minor 79 antibody presence and Rh status of the recipient, and for platelet transfusion was the platelet 80 count ($\leq 10k/\mu L$, >10 to $\leq 50k/\mu L$ and >50 to $\leq 150k/\mu L$).

81 Outliers in the time series data were detected utilizing the 'anomalize' R package 82 (version 0.2.2) on R (version 4.0.5). To accommodate for seasonal and trend changes and to find 83 the outliers, data were decomposed using locally estimated scatterplot smoothing (LOESS) and 84 turned into remainder values (R) which were compared to their remainder limits (Rlim) obtained 85 using generalized extreme studentized deviate (GESD) test. R and Rlim were calculated using 86 default alpha (width of the normal range), frequency and trend window settings (0.05, 12 to 13 87 weeks and 30 to 45 weeks, respectively). Maximum number of outliers permitted were 2 percent 88 of the data. Results are expressed in mean (standard deviation [SD]) or median (minimum [min], 89 maximum [max]), as appropriate. The study was conducted under Children's National Hospital 90 Institutional Review Board approved study protocol (Pro00010083-Mod00000781 'effectiveness 91 of blood product transfusion and associated adverse events in neonatal & paediatric patients'). A 92 two-tailed Student's *t*-test was performed to assess for significance for continuous variables.

93

94 Results

95 Over the two years and eight months period, 1,587 patients received 10,946 RBC 96 transfusions and 730 patients received 7,704 platelet transfusions within 24 hours of a 97 haemoglobin or a platelet count result, and patients were aged 11.1 years (SD: 7.03) and 10.8 98 years (SD: 7.03), respectively. Average volume of RBC transfusion was 251.7 mL (SD: 95.8), 99 average platelet transfusion volume was 148.9 mL (SD: 79.2), and time to initiate a transfusion 100 was 11.1 hours (SD: 6.82) and 11.1 hours (SD: 7.14), respectively. Mean time to initiate a 101 transfusion was shorter for patients with haemoglobin <7 g/dL (8.67 hours [SD: 5.46]) and 102 platelet count $\leq 10 \text{k/}\mu\text{L}$ (7.52 hours [SD: 6.3]) than haemoglobin $\geq 7 \text{ g/dL}$ (11.83 hours [SD: 103 6.99]) and platelet count >10k/ μ L (11.76 hours [SD: 7.09]) (both P: <0.001). On average there 104 were 79 (SD: 25) RBC and 55 (SD: 20) platelet transfusions per week.

Dates of outliers for the median time to initiate an RBC or a platelet transfusion after a CBC result were reported in Table 1 and were visualized in Figure 1. Overall, aggregated data assessment demonstrated that there was one outlier week (2020-10-12 to 2020-10-18, R: 7.48 [*Rlim:* -6.53 — 6.44]) for all RBC transfusions and none for all platelet transfusions.

Investigation of the subgroup data showed that RBC transfusions based on haemoglobin values showed only one outlier week (2020-07-20 to 2020-07-26, *R*: 6.0 [*Rlim*: -5.46 — 5.62]) for a haemoglobin value less than 7 g/dL and none for haemoglobin values \geq 7 g/dL. Patients with RBC minor antibodies who received RBC transfusion did not have outliers but patients without RBC minor antibodies had two outlier weeks (2021-08-09 to 2021-08-15, *R*: 7.03; 2022-114 07-11 to 2022-07-16, *R*: -7.31 [*Rlim*: 6.47 — 6.13]). A single week was noted to be an outlier

115 (2020-10-12 to 2021-08-15, R: 7.84 [Rlim: -7.38 - 7.07]) for RBC transfusions for Rh positive 116 patients whereas no outlier weeks were noted for Rh negative patients' RBC transfusions. 117 Assessment of the subgroup platelet transfusions based on pre-transfusion platelet count 118 identified eleven weeks with outliers (2020-05-25 to 2020-05-31, R: 9.84; 2020-09-07 to 2020-119 09-13, R: 10.7; 2020-09-14 to 2020-09-20, R: 9.73; 2020-10-12 to 2020-10-18, R: 13.5; 2021-06-120 21 to 2021-06-27, R: 7.11; 2021-08-30 to 2021-09-05, R: 13.7; 2022-01-17 to 2022-01-23, R: 121 8.58; 2022-01-31 to 2022-02-06, R:12.4; 2022-02-07 to 2022-02-13, R: 6.55; 2022-05-02 to 122 2022-05-08, R: 8.63; 2022-08-08 to 2022-08-14, R: 5.66 [Rlim: -5.93 - 5.41]) for platelet count 123 $\leq 10 \text{ k/\mu L}$. No outlier weeks were found for platelet transfusions for patients with $>10 \text{ k/\mu L}$ to 124 \leq 50k/µL platelet counts, however, two weeks were identified as outliers (2021-10-11 to 2021-125 10-17, R: 13.7; 2022-07-11 to 2022-07-17, R: 14.6 [*Rlim*: -12.1 — 11.9]) for platelet transfusions 126 for patients with a platelet count >50 k/ μ L and \leq 150 k/ μ L.

127

128 Discussion

129 Transfusion medicine service's contingency strategies to mitigate blood shortages 130 depends on the degree of the blood supplier's inventory (e.g., mild: <25% lower, moderate: 25% 131 to 50% lower, severe: 50% to 75% lower) and duration of the shortage (e.g., short term: <2132 weeks, long-term: >2 weeks) and includes action items such as lowering transfusion thresholds, 133 restricting orders, preventing wastage, splitting units, recommending pharmacological 134 alternatives, recommending cancelation of non-essential high blood use surgeries, placing upper-135 limits on blood use for procedures, limiting number of available units at the remote storage 136 refrigerators, lowering the minimum platelet yield required for the hospital to bring a unit into

inventory, re-evaluating maintenance RBC exchange for sickle cell disease patients, and as a lastresort extending shelf-life of blood products (6-8).

139 Modern machine learning (ML) tools are proposed to help manage operations by 140 translating big data into actionable information (9). Many organizations identified successful use 141 cases for ML tools during the throes of COVID-19 pandemic management (10). Within 142 haematology and transfusion medicine, trend analyses and outlier detections are ML tools which 143 could be utilized to evaluate transfusion delays. Using our proposed metric 'weekly median time 144 to initiate a transfusion based on an informative laboratory test result', we have observed trends 145 and identified numerous outliers based on: haemoglobin level, RBC minor antibody presence, Rh 146 status, and platelet count of the patient. Although the number of outlier events were small (one 147 for all RBC transfusions and none for all platelet transfusions), the subgroup analyses for 148 haemoglobin <7g/dL RBC transfusions and platelet count $\leq 10k/\mu L$ platelet transfusions showed 149 three and seven outlier weeks, respectively.

150 Delays causing major morbidity in provision of blood were noted in seven patients in the 151 2021 SHOT report. Five cases were included in the avoidable delays category whereas 14 cases 152 noted in the unavoidable delays category (3). Our transfusion medicine service at Children's 153 National Hospital was not notified about any severe adverse events due to provision or 154 unavailability of blood for the dates noted as outliers. We propose that the hospital transfusion 155 medicine committees to consider time to initiate a blood transfusion from a laboratory test result 156 which is affecting transfusion decision making (e.g., haemoglobin level or platelet count) as a 157 metric to evaluate trends and outliers in patient's access to blood products. This information 158 could then be used to conduct investigations for possible missed patient adverse events and be 159 used to address the root cause of the delays or fluctuations in transfusion timing. Furthermore,

- 160 we propose conducting subgroup assessments (e.g., haemoglobin <7g/dL and platelet count
- 161 $\leq 10k/\mu L$ transfusions), as we have observed broad analyses might miss significant events for
- 162 patient subgroups.
- 163
- 164
- 165 References

1661.Rajbhandary S, Andrzejewski C, Fridey J, Stotler B, Tsang HC, Hindawi S, et al. Incorporating the167entity of under-transfusion into hemovigilance monitoring: Documenting cases due to lack of inventory.

168 Transfusion. 2022;62(3):540-5.

169 2. Definitions of current SHOT reporting categories & what to report [July 20, 2022]. Available

170 from: <u>https://www.shotuk.org/wp-content/uploads/myimages/SHOT-Definitions-active-January-</u>

- 171 <u>2022.pdf</u>.
- SHOT Annual Report 2021 [cited July 20, 2022. Available from: <u>https://www.shotuk.org/wp-</u>
 <u>content/uploads/myimages/SHOT-REPORT-2021-FINAL-bookmarked.pdf.</u>
- 4. Preventing transfusion delays in bleeding and critically anaemic patients [July 20, 2022].Available from:
- 176https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=103881775.
- Bahar B, Gehrie EA, Mo YD, Jacquot C, Delanay M. Measuring the Impact of a Blood Supply
 Shortage Using Data Science. J Appl Lab Med. 2022.DOI: 10.1093/jalm/jfac084
- 180 6. Cohn CS, Pagano MB, Allen ES, Frey KP, Gniadek T, Lokhandwala PM, et al. How do I manage
 181 long-term blood component shortages in a hospital transfusion service? Transfusion. 2020;60(9):1897182 904.
- 183 7. McGinnis E, Guo RJ, Marcon KM, Berry B, Coupland R, Meneghetti V, et al. Adaptations of
- transfusion systems to the COVID-19 pandemic in British Columbia, Canada: Early experiences of a large
 tertiary care center and survey of provincial activities. Transfusion. 2021;61(4):1102-11.
- 1868.Saillant NN, Kornblith LZ, Moore H, Barrett C, Schreiber MA, Cotton BA, et al. The National Blood187Shortage-An Impetus for Change. Ann Surg. 2022;275(4):641-3.
- 1889.McAfee A, Brynjolfsson E. Big data: the management revolution. Harv Bus Rev. 2012;90(10):60-1896, 8, 128.
- 19010.Piccarozzi M, Aquilani B. The role of Big Data in the business challenge of Covid-19: a systematic191literature review in managerial studies. Procedia Comput Sci. 2022;200:1746-55.
- 192
- 193
- 194
- 195

- 196 Table 1. Dates of outliers for weekly median time to initiate a red blood cell or a platelet
- 197 transfusion following a haemoglobin, or a platelet count result and based on the haemoglobin
- 198 level, red blood cell minor antibody presence, Rh status, and platelet count of the patient.

Variable		Dates of outliers	R	Rlim
All RBC transfusions		2020-10-12 to 2020-10-18	7.48	-6.53 — 6.44
RBC transfusions based on haemoglobin level				
	<7g/dL	2020-07-20 to 2020-07-26	6.0	-5.46 — 5.61
	$\geq 7g/dL$	None		
RBC transfusions and antibody presence				
	Antibody positive	None		
	Antibody pogetive	2021-08-09 to 2021-08-15	7.03	-6.47 — 6.13
	- Antibody negative	2022-07-11 to 2022-07-17	-7.31	-6.47 — 6.13
RBC transfusion and Rh status of recipient				
	Rh positive	2020-10-12 to 2021-08-15	7.84	-7.38 — 7.07
	Rh negative	None		
All platelet transfusions		None		
Platelet transfusions based on platelet count				
		2020-05-25 to 2020-05-31	9.84	-5.93 - 5.41
	$\leq 10 k/\mu L$	2020-09-07 to 2020-09-13	10.7	-5.93 — 5.41
		2020-09-14 to 2020-09-20	9.73	-5.93 - 5.41

		2020-10-12 to 2020-10-18	13.5	-5.93 — 5.41
		2021-06-21 to 2021-06-27	7.11	-5.93 — 5.41
		2021-08-30 to 2021-09-05	13.7	-5.93 — 5.41
		2022-01-17 to 2022-01-23	8.58	-5.93 — 5.41
		2022-01-31 to 2022-02-06	12.4	-5.93 — 5.41
		2022-02-07 to 2022-02-13	6.55	-5.93 — 5.41
		2022-05-02 to 2022-05-08	8.63	-5.93 — 5.41
		2022-08-08 to 2022-08-14	5.66	-5.93 — 5.41
	>10 to \leq 50k/µL	None		
	$-$ >50 to \leq 150k/µL	2021-10-11 to 2021-10-17	13.7	-12.1 — 11.9
		2022-07-11 to 2022-07-17	14.6	-12.1 — 11.9
RBC: red blood ce	ell; <i>R</i> : remainder val	lue; <i>Rlim</i> : remainde	er limits	

209 Figure 1. Visual representation of outlier weeks of median time to initiate a red blood cell or a

210 platelet transfusion following a haemoglobin, or a platelet count result and based on the

- 211 haemoglobin level, red blood cell minor antibody presence, Rh status, and platelet count of the
- 212 patient.























anomaly

No

Yes